GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (STU:04X) » Definitions » Total Liabilities

Personalis (STU:04X) Total Liabilities : €68.62 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Personalis Total Liabilities?

Personalis's Total Liabilities for the quarter that ended in Mar. 2024 was €68.62 Mil.

Personalis's quarterly Total Liabilities increased from Sep. 2023 (€70.68 Mil) to Dec. 2023 (€87.72 Mil) but then declined from Dec. 2023 (€87.72 Mil) to Mar. 2024 (€68.62 Mil).

Personalis's annual Total Liabilities declined from Dec. 2021 (€76.31 Mil) to Dec. 2022 (€70.39 Mil) but then increased from Dec. 2022 (€70.39 Mil) to Dec. 2023 (€87.72 Mil).


Personalis Total Liabilities Historical Data

The historical data trend for Personalis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis Total Liabilities Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 45.54 41.02 76.31 70.39 87.72

Personalis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.36 67.34 70.68 87.72 68.62

Personalis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Personalis's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=43.314+(35.14+9.264
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=87.72

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=206.416-118.697
=87.72

Personalis's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.863+(34.439+5.313
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=68.62

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=179.654-111.038
=68.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Personalis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (STU:04X) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.

Personalis (STU:04X) Headlines

No Headlines